Publication:

A comparative study of efficacy of atorvastatin, rosuvastatin, and atorvastatin + fibrates as lipid lowering agents

Background Hypercholesterolemia patients are at high risk of coronary heart disease. National cholesterol education programme (NCEP) Adult Treatment Panel III guidelines provide the option of aggressively lowering Low-density cholesterol in them. Presently the standard therapy of hypercholesterolemia is by HMG co-A reductase inhibitors. Present study shows that Rosuvastatin is better than Atorvastatin, Atorvastatin and Fibrate is better than Atorvastatin monotherapy in management of hypercholesterolemia.

Methods The present research was an observational study conducted at Government general hospital, Nizamabad. A total of 150 patients on treatment for hypercholesterolemia for more than one year were enrolled in our study. They were divided into three groups. Group I: Atorvastatin (20 mg) (n=96; 64%); Group II: Rosuvastatin 10 mg (n= 41; 27.33%); Group III: Atorvastatin (20 mg) + Fibrate (145 mg) (n=13; 8.66%).

Results Rosuvastatin is better than Atorvastatin and Atorvastatin with fibrates reduces LDL, TG more than Atorvastatin alone.

Conclusions Rosuvastatin is better than Atorvastatin and Combination of atorvastatin with fibrates reduces LDL-Cholesterol and triglycerides more than atorvastatin alone.